369 related articles for article (PubMed ID: 21448103)
1. Myths and realities of continuous dopaminergic stimulation.
Pirtošek Z
Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
[TBL] [Abstract][Full Text] [Related]
2. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Olanow CW; Obeso JA; Stocchi F
Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
[TBL] [Abstract][Full Text] [Related]
4. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
5. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
7. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
Stocchi F
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012
[TBL] [Abstract][Full Text] [Related]
9. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Schwartz M; Sabetay S
Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
[TBL] [Abstract][Full Text] [Related]
10. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
12. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease.
Wolters ECh
Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S18-23. PubMed ID: 17702631
[TBL] [Abstract][Full Text] [Related]
13. Continuous dopaminergic stimulation--from theory to clinical practice.
Antonini A
Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S24-8. PubMed ID: 17702632
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of motor fluctuations in Parkinson's disease.
Widnell K
Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
[TBL] [Abstract][Full Text] [Related]
15. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
16. Treatments for Parkinson disease--past achievements and current clinical needs.
Poewe W
Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
[TBL] [Abstract][Full Text] [Related]
17. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Nutt JG; Carter JH; Lea ES; Woodward WR
Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
[TBL] [Abstract][Full Text] [Related]
18. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.
Wright BA; Waters CH
Expert Rev Neurother; 2013 Jun; 13(6):719-29. PubMed ID: 23739008
[TBL] [Abstract][Full Text] [Related]
19. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
20. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Jenner P
Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
